Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.

Harpreet Singh BhatiaJoseph BaileyOzan UnluKatherine HoffmanRobert J Kim

Published in: Pacing and clinical electrophysiology : PACE (2019)

In our study, DOACs appeared to be as efficacious and safe in CKD IV and V as in CKD III. In addition, DOACs appeared to be more effective than, and as safe as warfarin when compared with reference studies of patients with advanced CKD. Our findings support the use of DOACs for thromboembolism prevention in patients with advanced CKD and AF.

Keyphrases

direct oral anticoagulants
chronic kidney disease
atrial fibrillation
venous thromboembolism
end stage renal disease